Dyno introduces Lambda-1 capsid model and gene-payload screening service

Dyno Therapeutics announced its Lambda-1 capsid model and Dyno GPS genetic-payload screening service on November 18 at the Genetic Agency Technology Conference, according to its Business Wire release.
The tools target a preclinical problem in gene therapy: choosing a delivery shell, or capsid, and evaluating how genetic instructions behave before moving into human studies.
Dyno GPS lets developers submit payload sequences for testing with the company’s muscle and central-nervous-system capsids. Partners receive measurements of tissue distribution and payload expression, including comparisons with controls, from studies in mice and non-human primates.
Lambda-1 is described as a first-generation model for predicting capsid functions across a wider range of sequences. Dyno says it can help explore designs farther from naturally occurring capsids. Those claims do not establish effectiveness or safety in patients.
The announcement also highlights three previously presented AI-designed capsids available for licensing. The new service and model expand the tools developers can use to make delivery decisions, while leaving animal-to-human translation and clinical validation as separate challenges.
Sources and citations
Revision history
Published .